Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma

International Journal of Molecular Sciences

Volumn 11, Issue 12, 2010, Pages 5120-5128

  Maeda, Daichi ^a   Mao, Tsui Lien ^b   Fukayama, Masashi ^a   Nakagawa, Shunsuke ^c   Yano, Tetsu ^c   Taketani, Yuji ^c   Shih, Ie Ming ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF TOKYO   (Japan)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

ARID1A; Ovarian; Pathology

Indexed keywords

ARID1A; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; SENSITIVITY AND SPECIFICITY; WILD TYPE; ADENOCARCINOMA; AGE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; MUTATION; OVARY TUMOR; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA, CLEAR CELL; AGE FACTORS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 78650991499     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11125120     Document Type: Article

References (11)

1. Jones, S.; Wang, T.L.; Shih, I.M.; Mao, T.L., Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.; Vogelstein, B.; et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330, 228-231.
2. Wiegand, K.C.; Shah, S.P.; Al-Agha, O.M.; Zhao, Y.; Tse, K.; Zeng, T.; Senz, J.; McConechy, M.; Anglesio, M.S.; Kalloger, S.E.; et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010, 363, 1532-1543.
3. Kuo, K.; Mao, T.; Feng, Y.; Feng, Y.; Nakayama, K.; Wang, Y.; Glas, R.; Ma, J.; Kurman, R.J.; Shih, I.M.; et al. DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin. Cancer Res. 2010, 16, 1997-2008.
4. Wang, X.; Nagl, N.G.; Wilsker, D.; van Scoy, M.; Pacchione, S.; Yaciuk, P.; Dallas, P.B.; Moran, E. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem. J. 2004, 383, 319-325.
5. Ho, L.; Crabtree, G.R. Chromatin remodelling during development. Nature 2010, 463, 474-484.
6. van Rechem, C.; Boulay, G.; Leprince, D. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem. Biophys. Res. Commun. 2009, 385, 586-590.
7. Reisman, D.; Glaros, S.; Thompson, E.A. The SWI/SNF complex and cancer. Oncogene 2009, 28, 1653-1668.
8. Gao, X.; Tate, P.; Hu, P.; Tjian, R.; Skarnes, W.C.; Wang, Z. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc. Natl. Acad. Sci. USA 2008, 105, 6656-6661.
9. Nagl, N.G., Jr.; Patsialou, A.; Haines, D.S.; Dallas, P.B.; Beck, G.R.; Moran, E. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005, 65, 9236-9244.
10. Huang, J.; Zhao, Y.L.; Li, Y.; Fletcher, J.A.; Xian, S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chrom. Cancer 2007, 46, 745-750.
11. Veras, E.; Mao, T.L.; Ayhan, A.; Ueda, S.; Lai, H.; Shih, I.M.; Kurman, R.J. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: A clinicopathologic analysis of 122 cases. Am. J. Surg. Pathol. 2009, 33, 844-853.